Blood Res.  2014 Mar;49(1):1-2. 10.5045/br.2014.49.1.1.

Mantle cell lymphoma: a model for risk-adapted treatment approach

• Kim SJ

• KMID: 2172813
• DOI: http://doi.org/10.5045/br.2014.49.1.1

Abstract

No abstract available.

MeSH Terms

Lymphoma, Mantle-Cell*

Reference

1. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood. 2009; 114:1469–1476. PMID: 19556426.

2. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003; 3:185–197. PMID: 12620412.

3. Kang BW, Sohn SK, Moon JH, et al. Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: study by the Consortium for Improving Survival of Lymphoma. Blood Res. 2014; 49:15–21.

4. Ko YH, Kim CW, Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer. 1998; 83:806–812. PMID: 9708949.

5. Vose JM. Mantle cell lymphoma: 2013 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2013; 88:1082–1088. PMID: 24273091.

6. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005; 131:29–38. PMID: 16173960.

7. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008; 111:558–565. PMID: 17962512.

8. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381:1203–1210. PMID: 23433739.

9. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369:507–516. PMID: 23782157.

10. Brett LK, Williams ME. Current and emerging therapies in mantle cell lymphoma. Curr Treat Options Oncol. 2013; 14:198–211. PMID: 23512567.